70-Gene classifier for differentiation between paclitaxel- and docetaxel-sensitive breast cancers

Association of estrogen receptor (ER), progesterone receptor (PR), HER2, Ki67 and 70-gene classifier (70-GC) with a response to paclitaxel (PAC) (n = 79) or docetaxel (DOC) (n = 55) was investigated in the neoadjuvant setting for breast cancer patients. Sensitivity of breast tumors to PAC, but not to DOC, was found to be significantly associated with ER negativity (P = 0.003), PR negativity (P = 0.007), and Ki67 positivity (P = 0.007). Breast tumors classified into the responders by 70-GC showed a significantly (P = 0.005) higher reduction rate to PAC and interestingly a significantly (P = 0.009) lower reduction rate to DOC than those classified into the non-responders by 70-GC, suggesting that 70-GC might be useful for the differentiation of PAC-sensitive and DOC-sensitive breast tumors.